sponsored
PatientsVille.com Logo

PatientsVille

Spondylitis Medical Research Studies

Up-to-date List of Spondylitis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Spondylitis Medical Research Studies

Rank Status Study
1 Recruiting Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice
Condition: Ankylosing Spondylitis
Intervention:
Outcome Measures: Change in Bath Ankylosing Spondylitis Daily Activity Index (BASDAI);   Change in BASDAI 50 (Bath Ankylosing Spondylitis Daily Activity Index);   Change in Ankylosing Spondylitis Disease activity (ASDAS) score;   Change in the Number of hospital inpatient days;   Change in the Number of hospitalizations;   Change in the Number of sick leave days;   Change in the Number of sick leaves;   Change in the Number of outpatient visits to each kind of health care provider: general practitioner, rheumatologist, other specialists, physiotherapist, rheumatology nurse
2 Recruiting Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Drug: Tofacitinib 2 mg;   Drug: Tofacitinib 5 mg;   Drug: Tofacitinib 10 mg;   Drug: Placebo
Outcome Measures: Assessment in Ankylosing Spondylitis (ASAS) 20;   Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score and/or modified Berlin Ankylosing Spondlylitis Spine Magnetic Resonance Imaging Activity Score (ASspiMRI) of the SI joints and spine;   Assessment in Ankylosing Spondylitis (ASAS) 40;   Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6.;   Achieving Ankylosing Spondlylitis Disease Activity Score using C-Reactive Protein (ASDAS(CRP));   Achieving Ankylosing Spondlylitis Disease Activity Score (ASDAS) clinically important improvement;   Achieving Ankylosing Spondlylitis Disease Activity Score (ASDAS)major improvement;   Achieving Ankylosing Spondlylitis Disease Activity Score (ASDAS) inactive disease;   Bath Ankylosing Spondylitis Disease Activity Index (BASDAI);   Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 response;   Bath Ankylosing Spondylitis Functional Index (BASFI);   Bath Ankylosing Spondylitis Metrology Index (BASMI) Score;   Masstricht Ankylosing Spondylitis Enthesitis Score (MASES);   Extra-articular Involvement as assessed by swollen joints;   Spinal mobility as assessment by chest expansion;   36-Item Short-Form Health Survey (SF-36);   Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Day 1 and Week 12;   Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
3 Recruiting A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis
Condition: Spondylitis, Ankylosing
Intervention:
Outcome Measures: Effectiveness of adalimumab, measured as percentage of patients achieving Bath Ankylosing Spondylitis Disease Activity Index *BASDAI* 50 at week12 with adalimumab treatment.;   Effectiveness of adalimumab measured as change in BASDAI,Ankylosing Spondylitis Disease Activity Scores *ASDAS*,Visual Analogue Scale *VAS* in pain,Patient Global Assessment *PtGA* with adalimumab treatment.;   Proportion of patients who achieve each of the ASDAS disease state categories(inactive,mild,moderate,high) with adalimumab treatment.;   Improvement of extra-articular manifestation with adalimumab treatment compared to baseline: uveitis flare rates, patient proportion with VAS scale at 1 in IBD PtGA, patient proportion with skin lesion clear or almost clear in psoriasis PGA.;   BASDAI50 response rate at week 26 and week52 in patients still on adalimumab compared to patients who discontinued adalimumab early.;   Change in BASDAI, ASDAS, and VAS in pain and PtGA in patients still on adalimumab compared to patients who discontinued adalimumab early.;   Factors influencing the clinical response evaluated by the relapse rate(defined as BASDAI≥4) after discontinuation of adalimumab in patients who achieved BASDAI <4 and do not restart biologics in the follow-up
4 Recruiting Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
Condition: Ankylosing Spondylitis
Intervention: Other: no intervention
Outcome Measures: Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI);   Bath Ankylosing Spondylitis Disease Activity Index (BASDAI);   Ankylosing Spondylitis Quality of Life (ASQoL) Score;   Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score
5 Recruiting Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Condition: Ankylosing Spondylitis
Intervention:
Outcome Measures: Number of patients with adverse events;   Bath ankylosing Spondylitis Disease Activity Index;   Effectiveness evaluation by the investigator
6 Unknown  Clinical and Radiographic Correlation of Ultrasound MASEI Index in Patients With Ankylosing Spondylitis
Condition: Spondylitis, Ankylosing
Intervention:
Outcome Measure:
7 Unknown  European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study
Condition: Ankylosing Spondylitis
Intervention:
Outcome Measure:
8 Recruiting Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)
Condition: Ankylosing Spondylitis
Interventions: Drug: Adalimumab;   Drug: Methotrexate
Outcome Measures: presence or absence of antibodies against adalimumab;   Change from baseline of the Ankylosing Spondylitis Disease Activity Score (ASDAS);   Change from baseline of T and B cells concentrations.;   Change from baseline of "APRIL" and "TNF alpha" concentrations
9 Unknown  Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: infliximab
Outcome Measures: Degree of structural damage (radiographic progression)after 4 and 6 years of infliximab therapy (2 years of ASSERT trial plus 2 years of EASIC trial);   Proportion of patients which have received anti-TNF-alpha therapy as standard care after the end of ASSERT;   Description of the various treatment regimens after the end of ASSERT of the participating AS patients in various countries;   Degree of spinal inflammation analyzed by MRI after discontinuation of infliximab and 4-8 weeks and 2 and 4 years after re-treatment;   Long-term efficacy of infliximab over 4 and 6 years of therapy measured by the ASAS response criteria;   Efficacy and safety of a new start of infliximab therapy after discontinuation for several months after 2 and 4 years of continuous treatment;   Long-term effects on QoL;   Long-term effects on health resource utilisation and productivity in paid and unpaid work
10 Unknown  Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: abatacept
Outcome Measures: ASAS40 response rate in TNF-blocker naïve and in TNF-blocker failure patients;   Safety Evaluations: Adverse events, vital signs, physical examination results, and clinical laboratory values;   ASAS20 response;   ASAS partial remission criteria;   BASDAI 20 response;   BASDAI 50 response;   BASFI;   BASMI;   C-reactive protein;   erythrocyte sedimentation rate;   Quality of Life: SF-36, AS-QoL, EQ-5D;   Numeric Rating Scale (NRS) - physicians global, patients global, general pain, nocturnal pain;   Enthesitis index (Maastricht scale);   swollen and tender joint count;   Socio-economic questionnaire;   course of change of active and chronic inflammatory lesions in MRI
11 Recruiting Progression of Spinal Fusion in Ankylosing Spondylitis
Condition: Spondylitis, Ankylosing
Intervention:
Outcome Measure:
12 Recruiting Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
Condition: Ankylosing Spondylitis
Intervention:
Outcome Measure:
13 Unknown  Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: rituximab
Outcome Measures: Evaluation in week 24 and until study end: ASAS 20 in AS patients naïve to TNFalpha inhibitors as well as in AS patients with previous therapy with TNFalpha inhibitors.;   Safety Evaluations (Adverse events, vital signs, physical examination results, and clinical laboratory values until week 48);   Efficacy Evaluations:;   ASAS 40 response;   ASAS criteria for partial remission;   Duration of response;   BASDAI 20%, 50%, 70% improvement;   BASFI;   Mobility examinations;   BASMI;   Chest Wall Expansion;   disease controlling antirheumatic therapy criteria (DC-ART20) (5 out of 6);   CRP, ESR;   Quality of Life;   SF-36Numeric Rating Scale (NRS);   physicians global;   patients global;   general pain;   nocturnal pain Enthesitis index (Maastricht scale;   swollen joint countEQ-5D;   Socio-economic questionnairecourse of change of active and chronic inflammatory lesions in MRI after 24 weeks and after 48 weeksB cell analysis and T cell analysis
14 Not yet recruiting 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
Condition: Spondylitis, Ankylosing
Interventions: Biological: Secukinumab;   Biological: Placebo
Outcome Measures: Assessment of Spondyloarthritis International Society criteria / ASAS 20;   ASAS 40 response;   Serum hsCRP;   ASAS 5/6 response;   Bath Ankylosing Spondylitis Disease Activity Index / BASDAI;   Short Form-36 Physical Component Summary (SF-36 PCS) health survey;   Ankylosing Spondylitis Quality of Life (ASQoL);   ASAS partial remission;   Overall safety and tolerability
15 Recruiting Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
Conditions: Ankylosing Spondylitis;   Psoriatic Arthritis
Intervention:
Outcome Measures: Change in total work productivity impairment due to ankylosing Spondylitis and psoriatic arthritis;   Change in evolution of employment status and work productivity after initiation of adalimumab treatment between ankylosing Spondylitis and psoriatic arthritis patients throughout the study, measured by Work Productivity and Activity Impairment;   Evolution over time of work productivity: (observed for ankylosing Spondylitis and psoriatic arthritis combined and separately): Number of patients that are employed at each assessed visit;   Health Related Quality of Life - Health Assessment Questionnaire - Disability Index - Patient reported outcome (psoriatic arthritis);   Disease activity measures and clinical evaluations - Body Surface Area - psoriatic arthritis;   Health Related Quality of Life - Dermatology Life Quality Index - Patient reported outcome (psoriatic arthritis);   Health Related Quality of Life - Health Assessment Questionnaire modified for spondyloarthropathies - Patient reported outcome (ankylosing Spondylitis);   Disease activity measures and clinical evaluations - Disease Activity Score 28 - Psoriatic arthritis;   Disease activity measures and clinical evaluations - Bath Ankylosing Spondylitis Disease Activity Index - ankylosing Spondylitis;   Disease activity measures and clinical evaluations - Acute phase reactants (C-Reactive Protein / Erythrocyte Sedimentation Rate);   Disease activity measures and clinical evaluations - Visual Analogue Scale;   Evolution over time of work productivity:(observed for ankylosing Spondylitis and psoriatic arthritis combined and separately): Percentage of missed working hours (absenteeism) due to ankylosing Spondylitis/psoriatic arthritis 7 days prior to each visit;   Evolution over time of work productivity:(observed combined and separately):Assessment of the effect of ankylosing Spondylitis or psoriatic arthritis on the ability to do regular daily activities during the 7 days prior to each visit(activity impairment);   Evolution over time of work productivity: (observed combined and separately): Assessment of the effect of ankylosing Spondylitis or psoriatic arthritis on productivity while working during the 7 days prior to each visit (presenteeism)
16 Recruiting A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Biological: MSC;   Drug: "celecoxib", "Celebrex®"
Outcome Measures: the proportion of patients which disease activity reaches ASAS(assessment in ankylosing Spondylitis)20 remission criteria;   BASDAI score comparing to baseline;   BASFI score comparing to baseline
17 Recruiting Clinical Trial of Osteoporosis in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention:
Outcome Measures: The prevalence of osteoporosis and osteoporosis related fractures in patients with AS in Western Sweden.;   To investigate which method is the most reliable for measuring bone mineral density in ankylosing Spondylitis
18 Recruiting Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention:
Outcome Measures: Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Uveitis;   Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Inflammatory Bowel Disease;   Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Psoriasis;   Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Enthesitis of the Heel: Achilles Tendon and Plantar Fascia;   BASDAI (Bath AS Disease Activity Index);   BASFI (Bath AS Functional Assay);   PASQ (Psoriasis and Arthritis Screening Questionnaire)
19 Unknown  Prednisolone in Active Ankylosing Spondylitis (AS)
Condition: Ankylosing Spondylitis
Intervention: Drug: prednisolone
Outcome Measures: 50% improvement of BASDAI after 14 days of treatment;   Improvement of pain on a VAS 0 - 10;   Decrease of CRP/ BSG;   Number of swollen/tender joints;   number of enthesitic localisations;   improvement of function (BASFI);   improvement of quality of life (SF12)
20 Recruiting Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Biological: AIN457;   Biological: Placebo
Outcome Measures: Proportion of subjects achieving ASAS 20 response at week 16;   Proportion of subjects achieving ASAS 20 response at week 16 in whole study population;   Proportion of subjects achieving ASAS 40 response at week 16;   Proportion of subjects achieving ASAS 40 response at week 16 in whole study population

These studies may lead to new treatments and are adding insight into Spondylitis etiology and treatment.

A major focus of Spondylitis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Spondylitis